Citius Pharmaceuticals (CTXR) Cash from Operations (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Cash from Operations came in at 1300021.0 in Q1 2026, up 71.36% YoY from 758640.76 in Q1 2025, and up 90.01% on a QoQ basis from 13008822.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Cash from Operations (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Cash from Operations data on file, last reported at 1300021.0 in Q1 2026.
- Quarterly Cash from Operations rose 71.36% year-over-year to 1300021.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 31596253.0 (down 34.19% YoY) and the FY2025 annual result came in at 26552738.0, up 5.85% from the prior year.
- Cash from Operations advanced to 1300021.0 in Q1 2026, from 13008822.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1300021.0 in Q1 2026 to a low of 13008822.0 in Q4 2025.
- A 5-year average of 7166641.29 and a median of 6800215.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations slumped 175.27% — and 2026, when it jumped 71.36%.
- Tracing CTXR's Cash from Operations over 5 years: stood at 4824439.0 in 2022, then retreated by 27.17% to 6135310.0 in 2023, then gained by 22.97% to 4725852.0 in 2024, then tumbled by 175.27% to 13008822.0 in 2025, then jumped by 90.01% to 1300021.0 in 2026.
- The last three Cash from Operations figures came in at 1300021.0 (Q1 2026), 13008822.0 (Q4 2025), and 11880790.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | -13.01 Mn |
| Dec 31, 2025 | -13.01 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | -4.73 Mn |
| Dec 31, 2024 | -4.73 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Dec 31, 2023 | -6.14 Mn |
| Dec 31, 2023 | -6.14 Mn |